Indications
Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established.
Composition
- Active substance
- mitotane
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lysodren
- Active substance
- mitotane
- ATC code
- L01XX23
- Therapeutic area
- Adrenal Cortex Neoplasms
- Marketing authorisation holder
- Esteve Pharmaceuticals, S.A.
- Status
- Authorised